Stem Cells - Articles and news items

SMi group logo

12 months on: European Commission present updates on GDPR timelines and objectives at 7th annual BioBanking Industry Summit

Supplier news / 27 April 2017 / SMi Group

Legal advisor and policy analyst to provide opening keynote on the Impact of the General Data Protection Regulation (GDPR) on collaborative science in Europe…

Takeda makes €10 million equity investment in TiGenix

Industry news / 22 December 2016 / Niamh Louise Marriott, Digital Editor

TiGenix, has exercised the option granted by Takeda under the licensing agreement to make a €10 million equity investment in TiGenix…

Application note: Expansion of human bone marrow-derived mesenchymal stem cells in BioBLU 0.3c single-use bioreactors

Whitepapers / 16 December 2016 / Vincent Dufey, Aurélie Tacheny, Muriel Art and Françoise De Longueville, Eppendorf Application Technologies S.A., Namur, Belgium and Ulrike Becken, Eppendorf AG Bioprocess Center, Juelich, Germany

In this whitepaper Eppendorf discuss how the use of adult stem cells holds great promise for new cell-based therapies and drug discovery…

Stem cell nano drug delivery applications to treat diabetes

Stem cell nano drug delivery applications to treat diabetes

Drug Delivery, Issue 2 2016 / 4 May 2016 / Vishal Shahidadpury, Anjali Hirani and Yashwant Pathak - University of South Florida Health

Stem cell therapy is currently utilised in medicine for its application in tissue repair and regenerative medicine. Unique characteristics of stem cells, such as self-renewal and differentiation, allow its function to be applicable for therapeutic purposes. Nanotechnology and cell microencapsulation have been researched and used as a means to protect cells from innate immune responses while permitting targeted drug delivery, as well as for sustained release of therapeutic agents to specific organs or cells. This review will provide an overview of stem cells, the purpose of nanotechnology and various surface modifications of nanoparticles for enhanced drug delivery, as well as describe how stem cell therapy is used for type 1 and type 2 diabetes mellitus. Additionally, a specific application of nanoparticle encapsulation and human embryonic stem cells in achieving glycaemic control, as seen in type 1 diabetes-induced immune-competent mice, will be discussed…

First patient treated in trial of ReNeuron’s retinitis pigmentosa cell therapy

Industry news / 15 March 2016 / Victoria White

ReNeuron has demonstrated that its Human Retinal Progenitor Cells (hRPCs) improve visual acuity in preclinical models of retinal degeneration…

MS treatment, AHSCT, shows “remarkable” results

Industry news / 18 January 2016 / Victoria White

Autologous haematopoietic stem cell transplantation (AHSCT), developed at Sheffield Teaching Hospitals, has shown ‘remarkable’ results in patients with MS…

Stem cell therapy does not provide significant improvement in Crohn’s disease

Industry news / 17 December 2015 / Victoria White

A clinical trial to test the effectiveness of a stem cell therapy among adults with difficult to treat Crohn’s disease has found it is not significantly better than conventional treatment in producing sustained disease remission after one year…

Data from four trials support the safety and tolerability of hESC-derived retinal pigment epithelium

Industry news / 25 June 2015 /

Results of four trials provide additional evidence supporting the safety and tolerability of hESC-derived retinal pigment epithelium…

Trial of new stem cell therapy for dystrophic epidermolysis bullosa (RDEB) gives promising results

Industry news / 1 June 2015 /

Results from a trial of a new stem-cell based therapy for a rare skin condition, recessive dystrophic epidermolysis bullosa (RDEB), have been published…

Stem Cells Supplement

Stem Cells: In-depth focus 2015

Genomics, Issue 2 2015, Supplements / 20 April 2015 / Yu Wang, David Hay, Andreas Bender, Yasaman Kalantar Motamedi, Maryam Peymani, Mohammad Hossein

In this free-to-view stem cells in-depth focus, you can find out how computational (‘in silico’) methods can help to rationally choose bioactive small molecules to improve stem cell differentiation. The differentiation of pluripotent stem cells to hepatocyte-like cells is the focus of a second interesting article…

amd

Ocata Therapeutics licenses induced pluripotent stem cell (iPSC) technology from Allele Biotechnology

Industry news / 24 March 2015 / Victoria White

Ocata has announced that it has entered into a definitive agreement with Allele to access Allele’s proprietary technology for generating human iPSCs…

Promethera

Promethera Biosciences receives approval in Belgium to enroll patients in the imminent HEP002 Phase IIb/III clinical trial

Industry news / 15 October 2014 / Promethera Biosciences

HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+